Alvotech SA
NASDAQ:ALVO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.76
17.27
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Alvotech SA
PP&E Net
Alvotech SA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alvotech SA
NASDAQ:ALVO
|
PP&E Net
$356.6m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alvotech SA
Glance View
In the fiercely competitive world of pharmaceuticals, Alvotech SA has carved out a distinct niche as a specialist in developing biosimilars—essentially highly similar alternatives to already approved biological medicines. Based in Iceland, the company was founded by Robert Wessman, renowned for his successful ventures in the pharmaceutical industry. Alvotech strives to not only make crucial medications more accessible but to also alleviate the strain of high drug costs on healthcare systems worldwide. With its ardent focus on quality and efficacy, Alvotech's innovative research and development strategies underline its commitment to replicating complex biologics, ensuring they are more affordable without compromising on safety and effectiveness. Alvotech’s business model is intricately woven into the fabric of collaboration and partnership. Rather than attempting to market its products independently, Alvotech aligns with a network of global partners for commercialization and distribution, allowing the company to reach diverse markets efficiently. This approach not only widens their reach but also minimizes the cost and time associated with entering new geographical territories. Alvotech generates revenue by selling these biosimilars, capitalizing on the expiration of patents on original biologic drugs. In doing so, it provides healthcare providers and patients with cost-effective options, positioning itself as a valuable player in the increasingly essential biosimilar market.
See Also
What is Alvotech SA's PP&E Net?
PP&E Net
356.6m
USD
Based on the financial report for Dec 31, 2023, Alvotech SA's PP&E Net amounts to 356.6m USD.
What is Alvotech SA's PP&E Net growth rate?
PP&E Net CAGR 3Y
26%
Over the last year, the PP&E Net growth was 33%. The average annual PP&E Net growth rates for Alvotech SA have been 26% over the past three years .
You don't have any saved screeners yet
